The HSP90 inhibitor ganetespib radiosensitizes human lung adenocarcinoma cells

Cancers

Volumn 7, Issue 2, 2015, Pages 876-907

  Gomez Casal, Roberto ^a,b   Bhattacharya, Chitralekha ^a,b   Epperly, Michael W ^a,c   Basse, Per H ^a,c   Wang, Hong ^a,c   Wang, Xinhui ^d   Proia, David A ^e   Greenberger, Joel S ^a,c   Socinski, Mark A ^a,b   Levina, Vera ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Synta Pharmaceuticals Corp   (United States)

Author keywords

Apoptosis; Cell cycle; DNA repair; HSP90 inhibitor ganetespib; Ionizing radiation; Lung adenocarcinoma; Senescence; Xenografted tumors

Indexed keywords

BETA CATENIN; BETA GALACTOSIDASE; BIOLOGICAL MARKER; GANETESPIB; HIGH MOBILITY GROUP B1 PROTEIN; LIGHT CHAIN 3 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; RAD51 PROTEIN; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; WNT PROTEIN;

A549 CELL LINE; ADENOCARCINOMA CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; INFRARED RADIATION; LUNG ADENOCARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIZATION; SENESCENCE; SIGNAL TRANSDUCTION; T2821 CELL LINE; T2851 CELL LINE; TUMOR XENOGRAFT; UPREGULATION;

EID: 84934932194     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7020814     Document Type: Article

References (113)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65, 5–29.
2. Schiller, J.H.; Gandara, D.R.; Goss, G.D.; Vokes, E.E. Non-small-cell lung cancer: Then and now. J. Clin. Oncol. 2013, 31, 981–983.
3. Salama, J.K.; Vokes, E.E. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J. Clin. Oncol. 2013, 31, 1029–1038.
4. Grootjans, W.; de Geus-Oei, L.F.; Troost, E.G.; Visser, E.P.; Oyen, W.J.; Bussink, J. PET in the management of locally advanced and metastatic NSCLC. Nat. Rev. Clin. Oncol. 2015, doi:10.1038/nrclinonc.2015.75.
5. Richer, A.L.; Friel, J.M.; Carson, V.M.; Inge, L.J.; Whitsett, T.G. Genomic profiling toward precision medicine in non-small cell lung cancer: Getting beyond EGFR. Pharmacogenomics Pers. Med. 2015, 8, 63–79.
6. Sang, J.; Acquaviva, J.; Friedland, J.C.; Smith, D.L.; Sequeira, M.; Zhang, C.; Jiang, Q.; Xue, L.; Lovly, C.M.; Jimenez, J.P.; et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013, 3, 430–443.
7. Collins, L.G.; Haines, C.; Perkel, R.; Enck, R.E. Lung cancer: Diagnosis and management. Am. Fam. Phys. 2007, 75, 56–63.
8. Adebahr, S.; Collette, S.; Shash, E.; Lambrecht, M.; Le Pechoux, C.; Faivre-Finn, C.; de Ruysscher, D.; Peulen, H.; Belderbos, J.; Dziadziuszko, R et al. LungTech, an EORTC phase II trial of Stereotactic Body Radiotherapy for centrally located lung tumours—A clinical perspective. Br. J. Radiol. 2015, doi.org/10.1259/bjr.20150036.
9. Kan, Z.; Jaiswal, B.S.; Stinson, J.; Janakiraman, V.; Bhatt, D.; Stern, H.M.; Yue, P.; Haverty, P.M.; Bourgon, R.; Zheng, J.; et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466, 869–873.
10. Stea, B.; Gordon, J. Clinically relevant biomarkers in targeted radiotherapy. Clin. Exp. Metastasis 2012, 29, 853–860.
11. Johung, K.L.; Yao, X.; Li, F.; Yu, J.B.; Gettinger, S.N.; Goldberg, S.; Decker, R.H.; Hess, J.A.; Chiang, V.L.; Contessa, J.N. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer. Clin. Cancer Res. 2013, 19, 5523–5532.
12. Laine, A.M.; Westover, K.D.; Choy, H. Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer. Semin. Oncol. 2014, 41, 57–68.
13. Palmer, J.D.; Zaorsky, N.G.; Witek, M.; Lu, B. Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J. Thorac. Dis. 2014, 6, 387–398.
14. Withers, R. The Four R’s of Radiotherapy; Academic Press: New York, NY, USA, 1975; Volume 5.
15. Kanaar, R.; Hoeijmakers, J.H.; van Gent, D.C. Molecular mechanisms of DNA double strand break repair. Trends Cell Biol. 1998, 8, 483–489.
16. Bakkenist, C.J.; Kastan, M.B. Initiating cellular stress responses. Cell 2004, 118, 9–17.
17. Kanaar, R.; Wyman, C. DNA repair by the MRN complex: Break it to make it. Cell 2008, 135, 14–16.
18. Powell, S.; McMillan, T.J. DNA damage and repair following treatment with ionizing radiation. Radiother. Oncol. 1990, 19, 95–108.
19. Mladenov, E.; Magin, S.; Soni, A.; Iliakis, G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front. Oncol. 2013, 3, doi:10.3389/fonc.2013.00113.
20. Novotna, E.; Tichy, A.; Pejchal, J.; Lukasova, E.; Salovska, B.; Vavrova, J. DNA-dependent protein kinase and its inhibition in support of radiotherapy. Int. J. Radiat. Biol. 2013, 89, 416–423.
21. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8, 193–204.
22. Kong, F.M.; Zhao, J.; Wang, J.; Faivre-Finn, C. Radiation dose effect in locally advanced non-small cell lung cancer. J. Thorac. Dis. 2014, 6, 336–347.
23. Yi, B.S.; Perks, J.; Houston, R.; Stern, R.; Purdy, J.A.; Chen, A.M. Changes in position and volume of lung cancer target volumes during stereotactic body radiotherapy (SBRT): Is image guidance necessary? Technol. Cancer Res. Treat. 2011, 10, 495–504.
24. Fay, M.; Poole, C.M.; Pratt, G. Recent advances in radiotherapy for thoracic tumours. J. Thorac. Dis. 2013, 5, S551–S555.
25. Bertolaccini, L.; Terzi, A.; Ricchetti, F.; Alongi, F. Surgery or stereotactic ablative radiation therapy: How will be treated operable patients with early stage not small cell lung cancer in the next future? Ann. Transl. Med. 2015, 3, doi:10.3978/j.issn.2305-5839.
26. Bryant, C.M.; Albertus, D.L.; Kim, S.; Chen, G.; Brambilla, C.; Guedj, M.; Arima, C.; Travis, W.D.; Yatabe, Y.; Takahashi, T et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: An international validation study. PLoS ONE 2010, 5, e11712.
27. Shintani, Y.; Okimura, A.; Sato, K.; Nakagiri, T.; Kadota, Y.; Inoue, M.; Sawabata, N.; Minami, M.; Ikeda, N.; Kawahara, K et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann. Thorac. Surg. 2011, 92, 1794–1804.
28. Gomez-Casal, R.; Bhattacharya, C.; Ganesh, N.; Bailey, L.; Basse, P.; Gibson, M.; Epperly, M.; Levina, V. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol. Cancer 2013, 12, doi:10.1186/1476-4598-12-94.
29. Frydman, J. Folding of newly translated proteins in vivo: The role of molecular chaperones. Annu. Rev. Biochem. 2001, 70, 603–647.
30. Taipale, M.; Jarosz, D.F.; Lindquist, S. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 2010, 11, 515–528.
31. Pearl, L.H.; Prodromou, C.; Workman, P. The Hsp90 molecular chaperone: An open and shut case for treatment. Biochem. J. 2008, 410, 439–453.
32. Whitesell, L.; Lindquist, S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761–772.
33. Bishop, S.C.; Burlison, J.A.; Blagg, B.S. Hsp90: A novel target for the disruption of multiple signaling cascades. Curr. Cancer Drug Targets 2007, 7, 369–388.
34. Trepel, J.; Mollapour, M.; Giaccone, G.; Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10, 537–549.
35. Proia, D.A.; Bates, R.C. Ganetespib and HSP90: Translating preclinical hypotheses into clinical promise. Cancer Res. 2014, 74, 1294–1300.
36. Calderwood, S.K. Molecular cochaperones: Tumor growth and cancer treatment. Scientifica 2013, 2013, doi.org/10.1155/2013/217513.
37. Proia, D.A.; Zhang, C.; Sequeira, M.; Jimenez, J.P.; He, S.; Spector, N.; Shapiro, G.I.; Tolaney, S.; Nagai, M.; Acquaviva, J et al. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. Clin. Cancer Res. 2014, 20, 413–424.
38. Shimamura, T.; Shapiro, G.I. Heat shock protein 90 inhibition in lung cancer. J. Thorac. Oncol. 2008, 3, S152–S159.
39. Da Rocha Dias, S.; Friedlos, F.; Light, Y.; Springer, C.; Workman, P.; Marais, R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2005, 65, 10686–10691.
40. Zheng, F.F.; Kuduk, S.D.; Chiosis, G.; Munster, P.N.; Sepp-Lorenzino, L.; Danishefsky, S.J.; Rosen, N. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 2000, 60, 2090–2094.
41. Xu, W.; Soga, S.; Beebe, K.; Lee, M.J.; Kim, Y.S.; Trepel, J.; Neckers, L. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition. Br. J. Cancer 2007, 97, 741–744.
42. Normant, E.; Paez, G.; West, K.A.; Lim, A.R.; Slocum, K.L.; Tunkey, C.; McDougall, J.; Wylie, A.A.; Robison, K.; Caliri, K et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011, 30, 2581–2586.
43. Eiseman, J.L.; Lan, J.; Lagattuta, T.F.; Hamburger, D.R.; Joseph, E.; Covey, J.M.; Egorin, M.J. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino] geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 2005, 55, 21–32.
44. Chiosis, G. Targeting chaperones in transformed systems—A focus on Hsp90 and cancer. Expert Opin. Ther. Targets 2006, 10, 37–50.
45. Barrott, J.J.; Haystead, T.A. Hsp90, an unlikely ally in the war on cancer. FEBS J. 2013, 280, 1381–1396.
46. Proia, D.A.; Foley, K.P.; Korbut, T.; Sang, J.; Smith, D.; Bates, R.C.; Liu, Y.; Rosenberg, A.F.; Zhou, D.; Koya, K et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS ONE 2011, 6, e18552.
47. Ying, W.; Du, Z.; Sun, L.; Foley, K.P.; Proia, D.A.; Blackman, R.K.; Zhou, D.; Inoue, T.; Tatsuta, N.; Sang, J et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol. Cancer Ther. 2012, 11, 475–484.
48. Acquaviva, J.; Smith, D.L.; Sang, J.; Friedland, J.C.; He, S.; Sequeira, M.; Zhang, C.; Wada, Y.; Proia, D.A. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol. Cancer Ther. 2012, 11, 2633–2643.
49. Proia, D.A.; Sang, J.; He, S.; Smith, D.L.; Sequeira, M.; Zhang, C.; Liu, Y.; Ye, S.; Zhou, D.; Blackman, R.K et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Investig. New Drugs 2012, 30, 2201–2209.
50. Socinski, M.A.; Goldman, J.; El-Hariry, I.; Koczywas, M.; Vukovic, V.; Horn, L.; Paschold, E.; Salgia, R.; West, H.; Sequist, L.V et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin. Cancer Res. 2013, 19, 3068–3077.
51. Banerji, U. Heat shock protein 90 as a drug target: Some like it hot. Clin. Cancer Res. 2009, 15, 9–14.
52. Xu, W.; Neckers, L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin. Cancer Res. 2007, 13, 1625–1629.
53. He, S.; Smith, D.L.; Sequeira, M.; Sang, J.; Bates, R.C.; Proia, D.A. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Investig. New Drugs 2014, 32, 577–586.
54. Dontu, G.; Abdallah, W.M.; Foley, J.M.; Jackson, K.W.; Clarke, M.F.; Kawamura, M.J.; Wicha, M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17, 1253–1270.
55. Levina, V.; Marrangoni, A.M.; DeMarco, R.; Gorelik, E.; Lokshin, A.E. Drug-selected human lung cancer stem cells: Cytokine network, tumorigenic and metastatic properties. PLoS ONE 2008, 3, e3077.
56. Zhang, L.; Jiao, M.; Li, L.; Wu, D.; Wu, K.; Li, X.; Zhu, G.; Dang, Q.; Wang, X.; Hsieh, J.T et al. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J. Cancer Res. Clin. Oncol. 2012, 138, 675–686.
57. Bravo-Cordero, J.J.; Hodgson, L.; Condeelis, J. Directed cell invasion and migration during metastasis. Curr. Opin. Cell Biol. 2012, 24, 277–283.
58. Mizushima, N.; Yoshimori, T.; Levine, B. Methods in mammalian autophagy research. Cell 2010, 140, 313–326.
59. Scaffidi, P.; Misteli, T.; Bianchi, M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418, 191–195.
60. Dimri, G.P.; Testori, A.; Acosta, M.; Campisi, J. Replicative senescence, aging and growth-regulatory transcription factors. Biol. Signals 1996, 5, 154–162.
61. Machida, H.; Matsumoto, Y.; Shirai, M.; Kubota, N. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int. J. Radiat. Biol. 2003, 79, 973–980.
62. Russell, J.S.; Burgan, W.; Oswald, K.A.; Camphausen, K.; Tofilon, P.J. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: A multitarget approach to radiosensitization. Clin. Cancer Res. 2003, 9, 3749–3755.
63. Abdull Razis, A.F.; Iori, R.; Ioannides, C. The natural chemopreventive phytochemical R-sulforaphane is a far more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer. Int. J. Cancer 2011, 128, 2775–2782.
64. Gandhi, N.; Wild, A.T.; Chettiar, S.T.; Aziz, K.; Kato, Y.; Gajula, R.P.; Williams, R.D.; Cades, J.A.; Annadanam, A.; Song, D et al. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol. Ther. 2013, 14, 347–356.
65. Quanz, M.; Herbette, A.; Sayarath, M.; de Koning, L.; Dubois, T.; Sun, J.S.; Dutreix, M. Heat shock protein 90alpha (Hsp90alpha) is phosphorylated in response to DNA damage and accumulates in repair foci. J. Biol. Chem. 2012, 287, 8803–8815.
66. Schuurbiers, O.C.; Kaanders, J.H.; van der Heijden, H.F.; Dekhuijzen, R.P.; Oyen, W.J.; Bussink, J. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J. Thorac. Oncol. 2009, 4, 761–767.
67. Shimamura, T.; Perera, S.A.; Foley, K.P.; Sang, J.; Rodig, S.J.; Inoue, T.; Chen, L.; Li, D.; Carretero, J.; Li, Y.C et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin. Cancer Res. 2012, 18, 4973–4985.
68. Van Veelen, L.R.; Essers, J.; van de Rakt, M.W.; Odijk, H.; Pastink, A.; Zdzienicka, M.Z.; Paulusma, C.C.; Kanaar, R. Ionizing radiation-induced foci formation of mammalian Rad51 and Rad54 depends on the Rad51 paralogs, but not on Rad52. Mutat. Res. 2005, 574, 34–49.
69. Harper, J.V.; Anderson, J.A.; O’Neill, P. Radiation induced DNA DSBs: Contribution from stalled replication forks? DNA Repair 2010, 9, 907–913.
70. Rodier, F.; Munoz, D.P.; Teachenor, R.; Chu, V.; Le, O.; Bhaumik, D.; Coppe, J.P.; Campeau, E.; Beausejour, C.M.; Kim, S.H et al. DNA-SCARS: Distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J. Cell Sci. 2011, 124, 68–81.
71. Ko, J.C.; Chen, H.J.; Huang, Y.C.; Tseng, S.C.; Weng, S.H.; Wo, T.Y.; Huang, Y.J.; Chiu, H.C.; Tsai, M.S.; Chiou, R.Y et al. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells. Regul. Toxicol. Pharmacol. 2012, 64, 415–424.
72. Abbas, T.; Dutta, A. p21 in cancer: Intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9, 400–414.
73. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127, 469–480.
74. Stewart, D.J. Wnt signaling pathway in non-small cell lung cancer. J. Natl. Cancer Inst. 2014, 106, doi:10.1093/jnci/djt356.
75. Barginear, M.F.; Van Poznak, C.; Rosen, N.; Modi, S.; Hudis, C.A.; Budman, D.R. The heat shock protein 90 chaperone complex: An evolving therapeutic target. Curr. Cancer Drug Targets 2008, 8, 522–532.
76. Jhaveri, K.; Modi, S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv. Pharmacol. 2012, 65, 471–517.
77. He, S.; Zhang, C.; Shafi, A.A.; Sequeira, M.; Acquaviva, J.; Friedland, J.C.; Sang, J.; Smith, D.L.; Weigel, N.L.; Wada, Y et al. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int. J. Oncol. 2013, 42, 35–43.
78. Friedland, J.C.; Smith, D.L.; Sang, J.; Acquaviva, J.; He, S.; Zhang, C.; Proia, D.A. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Investig. New Drugs 2013, 32, 14–24.
79. Srethapakdi, M.; Liu, F.; Tavorath, R.; Rosen, N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res. 2000, 60, 3940–3946.
80. Liu, H.; Xiao, F.; Serebriiskii, I.G.; O’Brien, S.W.; Maglaty, M.A.; Astsaturov, I.; Litwin, S.; Martin, L.P.; Proia, D.A.; Golemis, E.A et al. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin. Cancer Res. 2013, 19, 5053–5067.
81. Acquaviva, J.; Smith, D.L.; Jimenez, J.P.; Zhang, C.; Sequeira, M.; He, S.; Sang, J.; Bates, R.C.; Proia, D.A. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Mol. Cancer Ther. 2014, 13, 353–363.
82. Smith, D.L.; Acquaviva, J.; Sequeira, M.; Jimenez, J.P.; Zhang, C.; Sang, J.; Bates, R.C.; Proia, D.A. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Targeted Oncol. 2014, doi:10.1158/1535-716.
83. Ewald, J.A.; Desotelle, J.A.; Wilding, G.; Jarrard, D.F. Therapy-induced senescence in cancer. J. Natl. Cancer Inst. 2010, 102, 1536–1546.
84. Campisi, J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol.2013, 75, 685–705.
85. Dorr, J.R.; Yu, Y.; Milanovic, M.; Beuster, G.; Zasada, C.; Dabritz, J.H.; Lisec, J.; Lenze, D.; Gerhardt, A.; Schleicher, K et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 2013, 501, 421–425.
86. Schmitt, C.A. Cellular senescence and cancer treatment. Biochim. Biophys. Acta 2007, 1775, 5–20.
87. Flores, J.M.; Martin-Caballero, J.; Garcia-Fernandez, R.A. p21 and p27 a shared senescence history. Cell Cycle 2014, 13, 1655–1656.
88. Chan, K.C.; Ting, C.M.; Chan, P.S.; Lo, M.C.; Lo, K.W.; Curry, J.E.; Smyth, T.; Lee, A.W.; Ng, W.T.; Tsao, G.S et al. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Mol. Cancer 2013, 12, doi:10.1186/1476-4598-12-128.
89. Li, F.; Tiede, B.; Massague, J.; Kang, Y. Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res. 2007, 17, 3–14.
90. Ridley, A.J.; Schwartz, M.A.; Burridge, K.; Firtel, R.A.; Ginsberg, M.H.; Borisy, G.; Parsons, J.T.; Horwitz, A.R. Cell migration: Integrating signals from front to back. Science 2003, 302, 1704–1709.
91. Teng, Y.; Wang, X.; Wang, Y.; Ma, D. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem. Biophys. Res. Commun. 2010, 392, 373–379.
92. Hartmann, S.; Gunther, N.; Biehl, M.; Katzer, A.; Kuger, S.; Worschech, E.; Sukhorukov, V.L.; Krohne, G.; Zimmermann, H.; Flentje, M et al. Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines. Cancer Lett. 2013, 331, 200–210.
93. Tsutsumi, S.; Scroggins, B.; Koga, F.; Lee, M.J.; Trepel, J.; Felts, S.; Carreras, C.; Neckers, L. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2008, 27, 2478–2487.
94. Lagadec, C.; Vlashi, E.; Della Donna, L.; Dekmezian, C.; Pajonk, F. Radiation-induced reprogramming of breast cancer cells. Stem Cells 2012, 30, 833–844.
95. Bastos, L.G.; de Marcondes, P.G.; de-Freitas-Junior, J.C.; Leve, F.; Mencalha, A.L.; de Souza, W.F.; de Araujo, W.M.; Tanaka, M.N.; Abdelhay, E.S.; Morgado-Diaz, J.A. Progeny from irradiated colorectal cancer cells acquire an EMT-Like phenotype and activate Wnt/beta-catenin pathway. J. Cell Biochem. 2014, 115, 2175–2187.
96. Findlay, V.J.; Wang, C.; Watson, D.K.; Camp, E.R. Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: Insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther. 2014, 21, 181–187.
97. Yan, S.; Wang, Y.; Yang, Q.; Li, X.; Kong, X.; Zhang, N.; Yuan, C.; Yang, N.; Kong, B. Low-dose radiation-induced epithelial-mesenchymal transition through NF-kappaB in cervical cancer cells. Int. J. Oncol. 2013, 42, 1801–1806.
98. Asuthkar, S.; Gondi, C.S.; Nalla, A.K.; Velpula, K.K.; Gorantla, B.; Rao, J.S. Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/beta-catenin signaling is enhanced in irradiated medulloblastoma cells. J. Biol. Chem. 2012, 287, 20576–20589.
99. Nguyen, P.; Lee, S.; Lorang-Leins, D.; Trepel, J.; Smart, D.K. SIRT2 interacts with beta-catenin to inhibit Wnt signaling output in response to radiation-induced stress. Mol. Cancer Res. 2014, 12, 1244–1253.
100. Watson, R.L.; Spalding, A.C.; Zielske, S.P.; Morgan, M.; Kim, A.C.; Bommer, G.T.; Eldar-Finkelman, H.; Giordano, T.; Fearon, E.R.; Hammer, G.D et al. GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. Neoplasia 2010, 12, 357–365.
101. Bonner, W.M.; Redon, C.E.; Dickey, J.S.; Nakamura, A.J.; Sedelnikova, O.A.; Solier, S.; Pommier, Y. GammaH2AX and cancer. Nat. Rev. Cancer 2008, 8, 957–967.
102. Rogakou, E.P.; Pilch, D.R.; Orr, A.H.; Ivanova, V.S.; Bonner, W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273, 5858–5868.
103. Pal, M.; Morgan, M.; Phelps, S.E.; Roe, S.M.; Parry-Morris, S.; Downs, J.A.; Polier, S.; Pearl, L.H.; Prodromou, C. Structural basis for phosphorylation-dependent recruitment of Tel2 to Hsp90 by Pih1. Structure 2014, 22, 805–818.
104. Ha, K.; Fiskus, W.; Rao, R.; Balusu, R.; Venkannagari, S.; Nalabothula, N.R.; Bhalla, K.N. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Mol. Cancer Ther. 2011, 10, 1194–1206.
105. Noguchi, M.; Yu, D.; Hirayama, R.; Ninomiya, Y.; Sekine, E.; Kubota, N.; Ando, K.; Okayasu, R. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem. Biophys. Res. Commun. 2006, 351, 658–663.
106. Zaidi, S.; McLaughlin, M.; Bhide, S.A.; Eccles, S.A.; Workman, P.; Nutting, C.M.; Huddart, R.A.; Harrington, K.J. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS ONE 2012, 7, e35436.
107. Fraser, M.; Harding, S.M.; Zhao, H.; Coackley, C.; Durocher, D.; Bristow, R.G. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 2011, 10, 2218–2232.
108. Epperly, M.W.; Wegner, R.; Kanai, A.J.; Kagan, V.; Greenberger, E.E.; Nie, S.; Greenberger, J.S. Effects of MnSOD-plasmid liposome gene therapy on antioxidant levels in irradiated murine oral cavity orthotopic tumors. Radiat. Res. 2007, 167, 289–297.
109. Levina, V.; Marrangoni, A.M.; Demarco, R.; Gorelik, E.; Lokshin, A.E. Multiple effects of TRAIL in human carcinoma cells: Induction of apoptosis, senescence, proliferation, and cytokine production. Exp. Cell Res. 2008, 314, 1605–1616.
110. Bhattacharya, C.; Wang, X.; Becker, D. The DEAD/DEAH box helicase, DDX11, is essential for the survival of advanced melanomas. Mol. Cancer 2012, 11, doi:10.1186/1476-4598-11-82.
111. Gokhale, A.; Rwigema, J.C.; Epperly, M.W.; Glowacki, J.; Wang, H.; Wipf, P.; Goff, J.P.; Dixon, T.; Patrene, K.; Greenberger, J.S. Small molecule GS-nitroxide ameliorates ionizing irradiation-induced delay in bone wound healing in a novel murine model. In Vivo 2010, 24, 377–385.
112. Kim, H.; Bernard, M.E.; Farkas, A.; Goff, J.; Kalash, R.; Houghton, F.; Shields, D.; Franicola, D.; Dixon, T.; Zhang, X et al. Ionizing irradiation protection and mitigation of murine cells by carbamazepine is p53 and autophagy independent. In Vivo 2012, 26, 341–354.
113. Hall, E.J.; Giaccia, A.J. Radiobiology for the Radiologist, 6th ed.; Lippincott Williams & Wilkins: New York, NY, USA, 2006